Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromocriptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.96 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromocriptine SCHEMBL29893478 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL40559 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL3393281 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL2405616 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL23468147 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL3134317 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL9526627 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL8032620 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL19276395 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL25297 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| WO-2023172561-A1 | USE OF BLINK REFLEX FOR PARKINSON'S DISEASE RESPONSE MONITORING AND/OR TREATMENT SELECTION | Blinktbi, Inc. (US) | 2023-09-14 | — | — | WO | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
| US-12622971-B2 | Linear polysaccharide based film products | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12616693-B2 | Bromocriptine formulations | VEROSCIENCE LLC (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260115254-A1 | IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF | VIB VZW (BE) | 2026-04-30 | — | — | US | disclosed |
| EP-3925602-B1 | CAPSULES WITH OPACIFIER | CAPSUGEL BELGIUM NV (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| US-20260109748-A1 | MODULATION OF DENDRITIC CELL LINEAGES | ORIONIS BIOSCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3580230-B1 | IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF | VIB VZW (BE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729055-A1 | TREATMENT OF DISORDERS USING SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) | 2026-04-22 | — | — | EP | disclosed |
| US-20220054426-A1 | DUAL LANE COATING | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3016684-B1 | REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES | H LUNDBECK AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | disclosed |
| US-11246911-B2 | Immune-cell targeted bispecific chimeric proteins and uses thereof | VIB VZW (BE) | 2022-02-15 | — | — | US | disclosed |
| US-20220040267-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | SANOFI SA (FR) | 2022-02-10 | — | — | US | disclosed |
| EP-3946410-A1 | THERAPEUTIC INTERFERON ALPHA 1 PROTEINS | Orionis Biosciences, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11241429-B2 | Method of treating metabolic disorders and depression with dopamine receptor agonists | VEROSCIENCE LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-11236141-B2 | Targeted mutant interferon-beta and uses thereof | Orionis Biosciences BV (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20220023392-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART | SANOFI SA (FR) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115254-A1 | IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF | SCTR, CSF1R, MSR1 | DRD3 3359/4885DRD2 2552/4885DRD4 3736/4885 |
| US-12616693-B2 | Bromocriptine formulations | GLP1R, PDE10A, MC2R | DRD3 30/4885DRD2 8/4885DRD4 38/4885 |
| US-20260109748-A1 | MODULATION OF DENDRITIC CELL LINEAGES | FCGR3B, VSIG8, TNFRSF9 | DRD3 1132/4885DRD2 1166/4885DRD4 1432/4885 |
| US-12622971-B2 | Linear polysaccharide based film products | SORD, SMCHD1, PLEC | DRD3 918/4885DRD2 744/4885DRD4 1364/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | DRD3 3019/4885DRD2 3587/4885DRD4 3650/4885 |
| US-11236141-B2 | Targeted mutant interferon-beta and uses thereof | IFNAR1, IFNG, STING1 | DRD3 4665/4885DRD2 4653/4885DRD4 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.